| Name | Title | Contact Details |
|---|
Accel Clinical Research is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vital Incite: Population Health Solutions, is a health care consulting firm offering the insight needed to strategically align healthcare resources to meet the needs of employee populations. Data is the driving force behind the Vital Incite Population Health Solution. We use it to: • Identify health risks trends within an employee population. • Understand how employees are accessing healthcare. • Evaluate the effectiveness of health benefit and wellness programs. • Hold ourselves and vendor partners accountable to improve health risks and expenses Our analytics tools turn health care data into actionable intelligence so that employers can make informed decisions about the health and wellness programs they offer to employees. Our analytics tools combine multiple data sources, including: • Claims Data (medical, dental, vision) • Health Risk Assessments • Biometric Data • Vendor Data We use what we learn from the data to develop program objectives, set impact expectations and track the effectiveness of the program. We are focused on the big picture, helping employers manage their health care spend and helping employees improve their health. We don`t try to solve employer problems with our own solutions. We identify which resources are required, assist an employer in choosing the provider of those resources and then continue to monitor the impact of those programs.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.
Advanced ENT and Allergy is a Louisville, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Complete Mobility Systems is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.